Diligence memo · auto-generated · as of July 2, 2026
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Areteia Therapeutics, Inc. operates in Biotechnology, based in CHAPEL HILL.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Areteia Therapeutics, Inc. has raised $360M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $360M on 2022-06-15.
Most recent recorded round closed around 2022-06-15.
Valuation (modeled)modeled
Provath models Areteia Therapeutics, Inc. at approximately $7.8B (range $1.6B–$13.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.87× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa, GIO World Health (Europe) Ltd.
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.